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ABSTRACT
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The present invention is also directed to a method of

SEVENTEEN AMINO ACID PEPTIDE

reducing the effect of an ischemic episode comprised of
administering an effective amount of pharmaceutically

(PEPTIDE P) FOR TREATING ISCHEMIA
AND REPERFUSION INJURY
FIELD OF THE INVENTION
The invention relates to the use of a novel seventeen

amino acid peptide to treat cerebral ischemia and ischemic

heart disease including reperfusion injury.
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BACKGROUND

body Weight to about 20 mg/kg body Weight, or alternatively

Tissues deprived of blood and oxygen undergo ischemic
necrosis or infarction With possible irreversible organ dam
age. Cerebral ischemia results from decreased blood and

effective amount of Peptide P to said mammal.
The present invention is also directed to a method of
treating cerebral or spinal cord ischemia or ischemic heart
disease in a mammal comprised of administering an effec
tive amount of pharmaceutically effective amount of Peptide
P to said mammal.
Preferably, Peptide P is administered as a pharmaceutical
composition at a dosage in the range of about 0.5 mg/kg

loWer doses in the range of about 1 mg/kg body Weight to
15

about 1000 mg/kg body Weight of the mammal. Preferably,
the mammal is human.

oxygen ?oW implicating one or more of the blood vessels of

the brain. In cerebral ischemia, the individual suffers a stroke

BRIEF DESCRIPTION OF THE DRAWING

With sudden development of a focal neurologic de?cit and,
The sole FIGURE accompanying the application is a
graph shoWing the effect of Peptide-P on infarct volume
folloWing cerebral ischemia.

in most cases, some degree of brain damage. The decreased
blood How may be due to, for example, an occlusion such as
a thrombus or embolus, vessel rupture, sudden fall in blood
pressure, change in the vessel lumen diameter due to

DESCRIPTION OF THE INVENTION

atherosclerosis, trauma, aneurysm, developmental
malformation, altered permeability of the vessel Wall or
increased viscosity or other quality of the blood. Decreased
blood How may also be due to failure of the systemic
circulation and severe prolonged hypotension. Ischemic
necrosis of the spinal cord may result in sensory or motor

25

Peptide P is a linear 17 amino acid peptide Which has been
synthesiZed on a commercial peptide synthesiZer such as the

type available from Applied Biosystem. Peptide P has the
amino acid sequence Tyr-D-Ala-Phe-Ala-Asp-Val-Ala-Ser
Thr-Ile-Gly-Asp-Phe-Phe-His-Ser-Ile-NH2 and a MW of
1860.1 With alanine as D-isomer. The peptide P can be
produced by a number of methods, such as by use of an

symptoms or both that can be referred to cervical, thoracic
or lumbar levels of the spine. Ischemic heart disease results

from an imbalance betWeen myocardial oxygen supply and
demand. In ischemic heart disease, the individual suffers

automated peptide synthesiZer, through recombinant
molecular biology techniques, or isolated from a naturally
occurring source.

angina pectoris, acute myocardial infarction or sudden
death. The imbalance may be caused by, for example,

Peptide P can be administered to ameliorate or inhibit
atherosclerotic obstruction of one or more large coronary 35 damage caused by a stroke. A stroke is the acute neurologic

arteries, nonatheromatous coronary obstructive lesions such

injury caused by one of several pathologic processes involv
ing the blood vessels of the brain. The pathologic process

as embolism, coronary ostial stenosis associated With luetic

aortitis, coronary artery spasm, congenital abnormalities of
the coronary circulation, increased myocardial oxygen
demands exceeding the normal supply capabilities as in
severe myocardial hypertrophy, reduction in the oxygen

may be intrinsic to the vessel itself such as in
arteriosclerosis, or may originate from a remote location
such as an embolus, or may result from decreased perfusion

or increased blood viscosity With inadequate cerebral blood

carrying capacity of the blood such as n anemia, or as a

consequence of inadequate cardiac perfusion pressure due to
hypotension from any cause. US. Pat. No. 6,294,579 B1

discloses methods for treating ischemia by administering
certain Deltorphin peptides. The publication by LaZarus et
al., “Environmental Health Perspectives”, Vol. 102, No. 4,
pages 648—654 (1994), discloses naturally occurring opiod

?oW, or may result from the rupture of a vessel in the
subarachnoid space or intracerebral tissue.
The main causes of ischemic stroke are thrombosis,
45
vasoconstriction and embolism. Diagnosis of a stroke can be

readily made by one of ordinary skill in the art. Signs of

stroke include paralysis, slurred speech, general confusion,
impairment of gait, cortical sensory loss over toes, foot and
leg and urinary incontinence, to name just a feW. The

peptides.
Current treatments for ischemia encompass behavioral

diagnosis can be con?rmed by cerebral angiography and by

changes drug therapy, and/or surgical intervention. Drugs
are frequently preferred before resorting to invasive proce
dures and to provide more immediate relief than long-term
behavioral changes. Thus, there is a need for a therapeutic
agent Which can be useful in treating or preventing ischemia.

a computed axial tomography (CT) scan of the brain.
If a stroke occurs, Peptide P can be administered to limit
55

SUMMARY OF THE INVENTION

It is an object of the invention to provide a novel peptide
and use of that peptide to treat ischemia.

The present invention meets the object by providing a
novel seventeen amino acid peptide (Peptide P) Which is
useful for treating cerebral ischemia and ischemic heart
disease. Also provided is a method of treating ischemia in a

mammal comprised administering a pharmaceutically effec
tive amount of Peptide P tc said mammal. The ischemic
tissue may be brain, spinal cord or heart.

65

injury to the brain. The ideal mode of administration is by
intravenous (IV) or intraperitoneal (I.P.) injection at a dose
of about 0.5—20 mg/kg, or alternatively, loWer doses of about
1—1000 mg/kg. Peptide P can also be administered by
subcutaneous or intraarterial injection into the carotid artery,
or by direct injection into the brain, e.g., intracerebroven
tricular injection (ICV) for dispersion into other areas.
Very often a stroke is caused by a cerebral embolism, the
likelihood of Which can frequently be predicted. In these
cases, the Peptide P can be administered prophylactically to
prevent or lessen the amount of brain tissue injured during
such an event. Many types of heart disease including cardiac
arrhythmias or diseases due to cardiac structural abnormali

ties may produce cerebral emboli. Atrial ?brillation from

US 6,544,950 B1
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any cause, including rheumatic valvular disease, may result
in emboli being produced Which can migrate into the arteries

advanced, preventative measures to control risk factors and
life style patterns associated With the disease are also

of the brain. Emboli formation and migration can occur as
a result of arteriosclerotic cardiovascular disease and myo

recommended. In patients in the symptomatic phase of the
disease, meticulous attention to life patterns or risk factors
must be given in an attempt to promote lesion regression or
at least prevent progression. Risk factors include a positive

cardial infarction. Emboli formation and migration can
occur as a result of arteriosclerotic cardiovascular disease

and myocardial infarction. Emboli formation is also a de?
nite risk for intracardiac surgery and prosthetic valve
replacement. Heart bypass surgery and angioplasty can
result in the formation of microemboli, Which can migrate

family history of ischemic heart disease, diabetes,
hyperlipidemia, hypertension, obesity and cigarette smok
ing. Life patterns include sedentary lifestyle, psychosocial
10

into the arteries of the brain and cause a series of occlusions

tension and certain personality traits.
Peptide P may be administered to asymptomatic individu

in a number or arteries, resulting in mental impairment.

als having one or more risk factors and/or life style patterns

Cerebral embolism is also the principal complication in the
transplant of arti?cial hearts. Furthermore, the overall risk of
stroke after any type of general surgery is 0.2 to 1 percent.
The vegetations of acute and subacute bacterial endocarditis

or to individuals already in the symptomatic phase of
ischemic heart disease to reduce or prevent disease progres
15

safety of others (e.g., commercial airline pilots) and that
present With questionable symptoms, suspicious or positive

can give rise to emboli, Which can occlude a major intrac

ranial artery. Thus, When these disease states or surgical
procedures are planned or are happening, Peptide P can be
administered to prevent brain damage due to any resultant
emboli and stroke.

sion. Additionally, Peptide P may be administered to the
folloWing patients: those having careers that involve the

20

noninvasive test results, and in Whom there are reasonable
doubts about the state of the coronary arteries; males Who

Peptide P can be administered to ameliorate or prevent

are 45 or older and females Who are 55 Will undergo valve
replacement and Who may or may not have clinical evidence

ischemic necrosis of the spinal cord. The ischemia may be
caused by an endarteritis of surface arteries leading to

cardial infarction because of the recurrence of angina, heart

thrombosis. Atherosclerotic thrombosis of the aorta or dis

of myocardial ischemia; and those at high risk after myo
25

secting aortic aneurysms may cause infarction of the spinal

cord (myelomalacia) by occluding nutrient arteries at
cervical, thoracic or lumbar levels, as can paralysis during
cardiac surgery requiring clamping of the aorta for more
than 30 minutes and aortic arteriography. Infarctive or

With other cardiac drugs such as nitrates, beta-adrenergic

blockers, calcium channel antagonists and/or aspirin and
30

hemorrhagic vascular lesions of the spinal cord
(hematomyelia) may result in the sudden onset of symptoms

35

or ischemic heart disease including reperfusion injury. Pep
tide P may be formulated for administration in an aqueous
based liquid such as phosphate buffered saline to form an
40

emulsion, or it may be formulated in an organic liquid such
as cyclodeXtrin or dimethylsulfoXide to form a solution. The

peptide-P active ingredient should be present in an effective

obstructive lesions such as embolism, coronary ostial steno
sis associated With luetic aortitis, coronary artery spasm, or
very uncommonly an arteritis of the coronary vessels. The

imbalance may also be due to congenital abnormalities of
the coronary circulation, an increase in myocardial oXygen

coronary arteriography and coronary artery bypass grafting.
According to the present invention, Peptide P is admin
istered to a mammal to treat cerebral or spinal cord ischemia

disease is a general term for a spectrum of diseases of

diverse etiology caused by an imbalance betWeen oXygen
supply and demand. The usual cause of the imbalance is
atherosclerotic obstruction of large coronary arteries, lead
ing to an absolute decrease in coronary artery blood ?oW. An
imbalance may also result from nonatheromatous coronary

either separately or in combination With ?brinolytic drugs
such as tissue plasminogen activator (tPA), streptokinase
and urokinase. Use of Peptide P may prolong life and/or
reduce or eliminate the need for invasive procedures such as

referable to sensory or motor or both spinal tract lesions.
Peptide P can also be administered to ameliorate or inhibit

damage caused by ischemic heart disease. Ischemic heart

failure, frequent ventricular premature contractions, or signs
of ischemia in the stress test, to name just a feW. Peptide P
may be administered either separately or in combination

amount of about 0.001 Wt. % up to 25.0 Wt. % in such
compositions. The solution or emulsion may be adminis
45

tered by any route, but it is preferably administered parenter
ally such as by intravenous, intramuscular, intradermal or

demands exceeding the supply capabilities in a normal
coronary circulation, a diminished oxygen-carrying capacity

intraperitoneal injections.

of the blood such as in anemia or in the presence of

mg/kg body Weight of the mammal to about 20 mg/kg body

carboXyhemoglobin (e. g., due to cigarette or cigar smoking),

A preferred Peptide P dose is in the range of about 0.5
50

Weight of the mammal, or alternatively loWer doses of about
1 mg/kg body Weight of the mammal to about 1000 mg/kg
body Weight of the mammal. The time of administration of
a single dose of Peptide P is preferably up to about four
hours after onset of an ischemic episode. HoWever, Peptide

55

P may be administered concurrently With the onset of a
ischemic episode or even prior to onset of ischemia and still

or as a consequence of inadequate perfusion pressure due to

hypotension. When ischemic events are transient, they may

be associated With angina pectoris: if prolonged, they can
lead to myocardial necrosis and scarring With or Without the

clinical picture of acute myocardial infarction. Ischemic
heart disease may be readily diagnosed by one skilled in the
art. There may be predictive changes in the
electrocardiogram, since ischemia alters electrical properties
of the heart. Such changes include inversion of the T Wave

and displacement of the ST segment. Another important
consequence of myocardial ischemia is electrical instability
leading to ventricular tachycardia or ventricular ?brillation.
Stress tests and coronary arteriography may also provide
diagnostic information. These diagnostic test results may
determine the need for Peptide P administration.

Since ischemic heart disease is usually asymptomatic
until the eXtent of coronary artery blockage is Well

60

produce a therapeutic effect.
Ef?cacy of Peptide P treatment may be evaluated using
noninvasive clinical imaging methods such as magnetic
resonance imaging (MRI) of the affected region to determine
the siZe of the damaged area. In cerebral ischemia, it is also
possible to assess neurologic de?cit by performance on

65

behavioral tests such as cognitive recognition or memory
function such as the National Institutes of Health (NIH)
stroke scale.

While the speci?c mechanism of Peptide P action on
ischemia is unknoWn, Peptide P eXhibits a speci?c and

US 6,544,950 B1
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reproducible effect on decreasing neurological de?cit and

Control animals (n=5) received I.V. injections of saline or

cerebral infarct volume. This invention Will be further

1% cyclodextrin. Peptide P treated animals (n=6) received 4
mg/kg of Peptide P 1 hour folloWing middle cerebral antery

appreciated in light of the folloWing example.
invention but the invention is not considered to be limited
thereto.

occlusion (MCAO). At time O, animals Were subjected to 1
hour focal middle cerebral arterial occlusion (MCAO)
ischemia and 24 hour of reperfusion. Cerebral blood Was

EXAMPLE

prior to ischemia and at 0.5 hour, 1 hour and 2 hours post

The folloWing example is presented to illustrate the

assessed by laser-Doppler ?oWmetry With a ?ber optic probe
ischemia. Ischemic volume Was measured and animals Were

A murine model of ischemia/reperfusion injury Was used
to evaluate the effects of Peptide P on cerebral blood ?oW,
behavioral changes and ischemia infarct volume.
Induction of Ischemia
Ischemia Was induced by transient occlusion of the exter

nal carotid artery (ECA). Male ICR mice Weighing about

10

15

30—35 g Were anesthetiZed With an intraperitoneal (i.p.)

injection of chloral hydrate (350 mg/kg of body Weight) and
xylaZine (4 mg/kg of body Weight). Rectal temperatures
Were maintained at 3710.5° C. With a heating pad and
incubator. The left femoral artery Was cannulated With a
PE-10 catheter for measurement of arterial blood pressure,

side at rest or no spontaneous motor activity (severe).
Evaluation of Treatment
Brain infarct volume Was measured after 1 hour of

ischemia and again at 24 hours after reperfusion. At the
20

pO2, pCO2 and pH.
A midline incision Was made in the skin of the neck and
the left common carotid artery (LCCA) Was exposed. The

ECA, superior thyroid artery (STA) and occipital artery

assessed for behavior changes using a numerical ranking
from 0 to 3 according to the folloWing criteria: 0=no
observable de?cits (normal); 1=failure to extend right fore
paW upon lifting by the tail (mild); 2=circling to the con
tralateral side (moderate); and 3=leaning to the contralateral

desired endpoint, the animal Was euthaniZed. The brain Was
immediately removed and placed into a mouse brain matrix
(ASI, Warren, MI) and 2 mm sections Were made. Brain
sections Were stained With 2% 2,3,5-triphenyltetraZolium
chloride (TTC). Infarct siZe Was determined according to the
formula:

25

(OA) Were isolated. The STA and OA Were electrocoagu

(Contralateral volume-ipsilateral undamaged volume)><100/Con—

lated using a cautery probe (Baster Hi Temp Cautery, Baxter

tralateral volume

Healthcare Corp.) and divided. The base of the ECA Was
secured With a microsurgical clip, then the distal end of the

to eliminate the effects of edema. Quantitation of contralat

placed in the end of the ECA, the surgical clip Was removed,

eral and ipsilateral volumes Was determined by image analy
sis using a Scion Image (NIH Image Version 1.59) modi?ed
by Scion Corp. and Adobe Photoshop 2.0.1.

then the blunted suture Was advanced into the ECA until
resistance Was detected. The blunted suture Was then tight

Statistical analysis of the volume analysis results Was
performed using the Student’s t-test or analysis of variance

ECA Was ligated With a 6-0 nylon suture and the ECA Was
cut. A blunted 5-0 blue mono?lament nylon suture Was

ened to prevent both slipping of the internal suture and

30

35

bleeding. The suture Was trimmed and the incision Was

sealed by suturing the skin. The suture remained in place for
varying lengths of time up to 24 h. At the desired time,
reperfusion of the brain (restoration of blood How to the
brain) Was accomplished by retreating the suture from the

Were expressed as mean1standard error of the mean (SEM)

Prior to Peptide P treatment, there Were no signi?cant
40

ECA.

Mean arterial blood pressure (MABP), p02, pCO2 and pH
Were measured before occlusion, 10 min after occlusion and
30 min after reperfusion. Cerebral blood How Was monitored

by laser-Doppler ?oWmetry With a ?ber optic probe placed

(ANOVA) folloWed by the Bonferroni test. Statistical sig
ni?cance Was assigned to comparisons of sections from
control versus Peptide P treated animals With p<0.006. Data

45

2 mm posterior and 6 mm lateral to the bregma on the

ipsilateral hemisphere of the brain.

differences in MABP, pO2, pCO2, pH or rectal temperature
betWeen control animals and deltorphin-treated animals.
Upon induction of ischemia by middle cerebral arterial
occlusion, both control and Peptide P- treated animals had a
25% reduction in cerebral blood ?oW Which Was sustained
for 1 hour during the ischemia. After cessation of ischemia,
cerebral blood ?oW returned to baseline levels Within 0.5
hour. Post ischemia, there Were no signi?cant differences in

MABP, pO2, pCO2, pH or rectal temperature betWeen

Treatment

The test compound Was Peptide P (Tyr-D-Ala-Phe-Ala

Asp-Val-Ala-Ser-Thr-Ile-Gly-Asp-Phe-Phe-His-Ser-Ile
NH2). For analysis of the test compound, a solution of the
test compound in saline or 1% cyclodextrin Was prepared.
The test compound in solution Was administered by I.V.
injection at multiple doses prior to or up to 4 hours folloWing

ischemic injury.

control animals and deltophin-treated animals. There Was,
50

hoWever, a signi?cant (<0.05) decrease in neurological
de?cits from Peptide P treated animals (0.44111) versus

control animals (15510.19). Additionally, infarct volume
Was also signi?cantly reduced by 59% in Peptide P- treated

animals (2414.8 mm3) compared to control animals (5817.2
mm3) after 24 h of reperfusion, see FIG. 1, Table 1 & 2.
TABLE 1

Peptide-P Pep-P
Mouse strain/C57
No.
Sex

Ischemia Time
Reperfusion Time
Cross Section Area 1
Cross Section Area 2

Pep-P Pep-P Pep-P Pep-P Pep-P Pep-P
1
M

2
M

3
M

4
M

5
M

6
M

1 hr
1 hr 1 hr 1 hr
1 hr
1 hr
24 hr 24 hr 24 hr 24 hr 24 hr 24 hr
10.43 9.53 10.74 13.46 11.00 11.71
17.91 16.64 17.44 19.06 18.11 18.8

Total

Average

US 6,544,950 B1
TABLE l-continued

Peptide-P Pep-P
Mouse strain/C57

Pep-P Pep-P Pep-P Pep-P Pep-P Pep-P

No.
SeX

1
M

Cross Section Area 3
Cross Section Area 4
Total Cross Section Area
Damaged Cross Section Area
Damaged Cross Section Area
Damaged Cross Section Area
Damaged Cross Section Area
Damaged Cross Section Area
Damaged %
Corrected Volume

2
M

3
M

4
M

5
M

6
M

Total

Average

19.77 19.62 19.46 20.7 21.19 21.3
20.43 18.93 19.26 19.73 20.85 20.73

1
2
3
4

68.54 64.72 66.9 72.95
3.69 0
1.42 1.89
5.66 0.32 1.38 3.27
6.47 1.12 2.63 7.23
1.84 1.11 3.06 5.54
17.66 2.55 8.49 17.93
25.77 3.94 12.69 24.58
35.32 5.10 16.98 35.86

71.15
0
4.59
2.22
6.11
12.92
18.16
25.84

72.54
0.27
1.8
5.15
4.46
11.68
16.10
23.36

416.8

68.77 1 1.4%

71.23 11.87 1 2.4%
101.24 16.87 1 3.3%
142.46 23.74 1 4.8% mm3

Corrected Volume (mm3) = Damaged Cross Section Area X 2 mm section

After 1 hr ischemia mice Were injected With 100 #1 Peptide-P (4 mg/Kg)

TABLE 2
Saline

Mouse strain/C57
No.
SeX

Ischemia Time
Reperfusion Time
Cross Section Area
Cross Section Area
Cross Section Area
Cross Section Area

1
2
3
4

Total Cross Section Area
Damaged Cross Section Area
Damaged Cross Section Area
Damaged Cross Section Area
Damaged Cross Section Area
Damaged Cross Section Area
Damaged %
Corrected Volume

1
2
3
4

Saline

Saline

Saline

Saline

Saline

1
M

2
M

3
M

4
M

5
M

1 hr
24 hr
14.81
22.52
25.24
24.51

1 hr
24 hr
14.65
22.39
25.45
24.05

1 hr
24 hr
12.55
19.52
21.84
21.54

1 hr
24 hr
13.18
20.68
23.51
24.98

1 hr
24 hr
15.35
22.08
24.77
23.81

87.08
6.58
9.7
11.86
10.02
38.16
43.82
76.32

86.54
4.49
6.86
10.7
12.22
34.27
39.60
68.54

75.45
1.77
2.42
7.65
9.03
20.87
27.66
41.74

82.35
1.02
2.21
5.79
11.21
20.23
24.57
40.46

86.01
4.83
8.81
9.52
8.26
31.42
36.53
62.84

Total

Average

417.43 83.49 1 2.2%

144.95 28.99 1 3.6%
172.18 34.45 1 3.6%
289.9 57.98 1 7.2% mm3

Corrected Volume (mm3) = Damaged Cross Section Area X 2 mm section

After 1 hr ischemia mice Were injected With 100 #1 physiological saline

Identi?cation of a novel seventeen amino acid Peptide,
Peptide P and a method for treating cerebral or spinal cord
ischemia or ischemic heart disease including reperfusion

45

injury by Peptide P administration is thus disclosed. Peptide

departing from the spirit of the invention and the scope of
the folloWing claims.

P, SEQ ID NO:1 is formulated for biocompatible adminis

What is claimed is:

tration in a preferred dose in the range of about 0.5—20

mg/kg, or alternatively 1—1000 mg/kg body Weight of the

skilled in the art and thus are not limiting in any Way.
Therefore various changes, modi?cations or alterations to
these embodiments may be made or restored to Without

50

1. Peptide P comprising the amino acid sequence, Tyr-D

animal. The Peptide P dose may be administered up to four
hours after the onset of an ischemic attack. Alternatively, the

Ala-Phe-Ala-Asp-Val-Ala-Ser-Thr-Ile-Gly-Asp-Phe-Phe

Peptide P dose may be administered prophylactically in

2. A pharmaceutical composition comprising a pharma
ceutically effective amount of Peptide P having the amino
acid sequence, Tyr-D-Ala-Phe-Ala-Asp-Val-Ala-Ser-Thr
Ile-Gly-Asp-Phe-Phe-His-Ser-Ile-NH2 and a pharmaceuti

patients at risk for an ischemic attack such as, for example,
prior to surgery. Peptide P administration reduces the effect
of an ischemic event.

It should be understood that the embodiments of the

present invention shoWn and described in the speci?cation
are only preferred embodiments of the inventors Who are

His-Ser-Ile-NH2.

55

cally acceptable carrier.

